2024
Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic
Faust J, Renton B, Bongiovanni T, Chen A, Sheares K, Du C, Essien U, Fuentes-Afflick E, Haywood T, Khera R, King T, Li S, Lin Z, Lu Y, Marshall A, Ndumele C, Opara I, Loarte-Rodriguez T, Sawano M, Taparra K, Taylor H, Watson K, Yancy C, Krumholz H. Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e2438918. PMID: 39392630, PMCID: PMC11581672, DOI: 10.1001/jamanetworkopen.2024.38918.Peer-Reviewed Original ResearchConceptsCOVID-19 public health emergencyNon-HispanicPublic health emergencyOther Pacific IslanderExcess mortalityAlaska NativesUS populationExcess deathsRates of excess mortalityCross-sectional study analyzed dataYears of potential lifeMortality relative riskNon-Hispanic whitesCross-sectional studyPacific IslandersStudy analyzed dataAll-cause mortalityEthnic groupsMortality disparitiesMortality ratioTotal populationDeath certificatesEthnic disparitiesMain OutcomesDecedent ageEffect of the COVID-19 Pandemic on Monitoring and Control of Cardiovascular Risk Factors and Disparities
Lu Y, Brush J, Liu Y, Li S, Asher J, Krumholz H. Effect of the COVID-19 Pandemic on Monitoring and Control of Cardiovascular Risk Factors and Disparities. JACC Advances 2024, 3: 101177. PMID: 39220712, PMCID: PMC11364117, DOI: 10.1016/j.jacadv.2024.101177.Peer-Reviewed Original ResearchThe PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Krumholz H, Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Coppi A, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Al Mouslmani M, Putrino D, Carr K, Carvajal-Gonzalez S, Charnas L, De Jesus M, Ziegler F, Iwasaki A. The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID. The American Journal Of Medicine 2024 PMID: 38735354, DOI: 10.1016/j.amjmed.2024.04.030.Peer-Reviewed Original ResearchLC trialPROMIS-29Participants' homesTargeting viral persistencePlacebo-controlled trialDouble-blind studyElectronic health recordsCore Outcome MeasuresLong COVIDEQ-5D-5LRepeated measures analysisEvidence-based treatmentsPhase 2Double-blindParticipant-centred approachStudy drugPrimary endpointSecondary endpointsCommunity-dwellingHealth recordsHealthcare utilizationContiguous US statesViral persistencePatient groupDrug treatmentHypertension Trends and Disparities Over 12 Years in a Large Health System: Leveraging the Electronic Health Records
Brush J, Lu Y, Liu Y, Asher J, Li S, Sawano M, Young P, Schulz W, Anderson M, Burrows J, Krumholz H. Hypertension Trends and Disparities Over 12 Years in a Large Health System: Leveraging the Electronic Health Records. Journal Of The American Heart Association 2024, 13: e033253. PMID: 38686864, PMCID: PMC11179912, DOI: 10.1161/jaha.123.033253.Peer-Reviewed Original ResearchConceptsElectronic health recordsRegional health systemImprove hypertension careHealth systemHealth recordsHypertension careDiastolic blood pressureAge-adjusted prevalence ratesNon-Hispanic Black patientsPrevalence ratesLarger health systemCross-sectional analysisTransformation of medical dataLeveraging real-world dataHigh prevalence rateHypertension trendsHypertension prevalenceBlood pressureBlood pressure measurementsHypertension diagnosisPrimary outcomeNational trendsProportion of patientsAntihypertensive medicationsBlack patientsPre-COVID-19 hospital quality and hospital response to COVID-19: examining associations between risk-adjusted mortality for patients hospitalised with COVID-19 and pre-COVID-19 hospital quality
Peter D, Li S, Wang Y, Zhang J, Grady J, McDowell K, Norton E, Lin Z, Bernheim S, Venkatesh A, Fleisher L, Schreiber M, Suter L, Triche E. Pre-COVID-19 hospital quality and hospital response to COVID-19: examining associations between risk-adjusted mortality for patients hospitalised with COVID-19 and pre-COVID-19 hospital quality. BMJ Open 2024, 14: e077394. PMID: 38553067, PMCID: PMC10982775, DOI: 10.1136/bmjopen-2023-077394.Peer-Reviewed Original ResearchConceptsHospital qualityPatient experiencePre-COVID-19Medicare patientsShort-term acute care hospitalsCritical access hospitalsAcute care hospitalsFuture public health emergenciesHigher odds of mortalityIn-hospitalRisk-adjusted mortalityOdds of mortalityCare deliveryAccess hospitalsEffective careCOVID-19-related deathsAssociated with mortalityCare structuresHospital characteristicsPublic health emergencySummary scoreMedicare beneficiariesHigher oddsHospital responseRSMRs
2023
State-Level Excess Mortality and Potential Deaths Averted in US Adults During the Delta and Omicron Waves of COVID-19
Renton B, Du C, Chen A, Li S, Lin Z, Krumholz H, Faust J. State-Level Excess Mortality and Potential Deaths Averted in US Adults During the Delta and Omicron Waves of COVID-19. Journal Of General Internal Medicine 2023, 39: 142-146. PMID: 37620716, PMCID: PMC10817860, DOI: 10.1007/s11606-023-08374-2.Peer-Reviewed Original Research
2022
Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group
Spatz E, Gottlieb M, Wisk L, Anderson J, Chang A, Gentile N, Hill M, Huebinger R, Idris A, Kinsman J, Koo K, Li S, McDonald S, Plumb I, Rodriguez R, Saydah S, Slovis B, Stephens K, Unger E, Wang R, Yu H, Hota B, Elmore J, Weinstein R, Venkatesh A. Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group. Clinical Infectious Diseases 2022, 76: 1559-1566. PMID: 36573005, PMCID: PMC11361781, DOI: 10.1093/cid/ciac966.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 symptomsSARS-CoV-2 infectionPost-infectious syndromesProspective cohort studyCohort studyCOVID groupAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 test resultsSyndrome coronavirus 2 infectionEar/nose/throatSevere acute respiratory syndrome coronavirus 2 testsCoronavirus 2 infectionLong-term symptomsNose/throatLong COVIDSymptomatic adultsMean ageActive symptomsSymptom profilesDrug AdministrationSociodemographic characteristicsSymptomsInfectionMonthsUncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state
Faust JS, Renton B, Chen AJ, Du C, Liang C, Li SX, Lin Z, Krumholz HM. Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state. The Lancet Infectious Diseases 2022, 22: 1419-1420. PMID: 36007530, PMCID: PMC9395168, DOI: 10.1016/s1473-3099(22)00547-3.Peer-Reviewed Original ResearchSex-Specific Risk Factors Associated With First Acute Myocardial Infarction in Young Adults
Lu Y, Li SX, Liu Y, Rodriguez F, Watson KE, Dreyer RP, Khera R, Murugiah K, D’Onofrio G, Spatz ES, Nasir K, Masoudi FA, Krumholz HM. Sex-Specific Risk Factors Associated With First Acute Myocardial Infarction in Young Adults. JAMA Network Open 2022, 5: e229953. PMID: 35503221, PMCID: PMC9066284, DOI: 10.1001/jamanetworkopen.2022.9953.Peer-Reviewed Original ResearchConceptsFirst acute myocardial infarctionAcute myocardial infarctionPsychosocial risk factorsRisk factor profilePopulation attributable fractionRisk factor associationsRisk factorsOdds ratioYoung womenAMI subtypesMyocardial infarctionPrevention of AMIType 1 acute myocardial infarctionFactor profileRisk of AMITraditional cardiovascular risk factorsSex-specific risk factorsFactor associationsYoung adultsRisk factor modificationCardiovascular risk factorsStrong associationNutrition Examination SurveyCase-control studyPopulation-based controlsLeading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020
Faust JS, Chen AJ, Tiako M, Du C, Li SX, Krumholz HM, Barnett ML. Leading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020. JAMA Internal Medicine 2022, 182: 87-90. PMID: 34807250, PMCID: PMC8609460, DOI: 10.1001/jamainternmed.2021.6734.Peer-Reviewed Original Research
2021
Performance Metrics for the Comparative Analysis of Clinical Risk Prediction Models Employing Machine Learning
Huang C, Li SX, Caraballo C, Masoudi FA, Rumsfeld JS, Spertus JA, Normand ST, Mortazavi BJ, Krumholz HM. Performance Metrics for the Comparative Analysis of Clinical Risk Prediction Models Employing Machine Learning. Circulation Cardiovascular Quality And Outcomes 2021, 14: e007526. PMID: 34601947, DOI: 10.1161/circoutcomes.120.007526.Peer-Reviewed Original ResearchDisparities in Excess Mortality Associated with COVID-19 — United States, 2020
Rossen LM, Ahmad FB, Anderson RN, Branum AM, Du C, Krumholz HM, Li SX, Lin Z, Marshall A, Sutton PD, Faust JS. Disparities in Excess Mortality Associated with COVID-19 — United States, 2020. MMWR Morbidity And Mortality Weekly Report 2021, 70: 1114-1119. PMID: 34411075, PMCID: PMC8375709, DOI: 10.15585/mmwr.mm7033a2.Peer-Reviewed Original ResearchConceptsMortality incidence ratesIncidence rateExcess mortalityAge groupsHighest excess mortality ratesExcess Mortality AssociatedGreater excess mortalityExcess mortality ratesAI/AN populationsNon-Hispanic American IndianNon-Hispanic blacksNational Vital Statistics SystemCOVID-19 pandemicPublic health messagingNon-Hispanic white populationRace/ethnicityVital Statistics SystemMortality AssociatedLack of adjustmentMortality rateExcess deathsAN populationsEthnic groupsHealth messagingHispanic personsMortality From Drug Overdoses, Homicides, Unintentional Injuries, Motor Vehicle Crashes, and Suicides During the Pandemic, March-August 2020
Faust JS, Du C, Mayes KD, Li SX, Lin Z, Barnett ML, Krumholz HM. Mortality From Drug Overdoses, Homicides, Unintentional Injuries, Motor Vehicle Crashes, and Suicides During the Pandemic, March-August 2020. JAMA 2021, 326: 84-86. PMID: 34019096, PMCID: PMC8140390, DOI: 10.1001/jama.2021.8012.Peer-Reviewed Original ResearchIncorporating Present-on-Admission Indicators in Medicare Claims to Inform Hospital Quality Measure Risk Adjustment Models
Triche EW, Xin X, Stackland S, Purvis D, Harris A, Yu H, Grady JN, Li SX, Bernheim SM, Krumholz HM, Poyer J, Dorsey K. Incorporating Present-on-Admission Indicators in Medicare Claims to Inform Hospital Quality Measure Risk Adjustment Models. JAMA Network Open 2021, 4: e218512. PMID: 33978722, PMCID: PMC8116982, DOI: 10.1001/jamanetworkopen.2021.8512.Peer-Reviewed Original ResearchConceptsPOA indicatorRisk factorsOutcome measuresQuality outcome measuresRisk-adjustment modelsClaims dataAdmission indicatorsPatient risk factorsAcute myocardial infarctionPatient-level outcomesAdministrative claims dataQuality improvement studyClaims-based measuresComparative effectiveness studiesPatient claims dataInternational Statistical ClassificationMortality outcome measuresRelated Health ProblemsHospital quality measuresRisk model performanceHospital stayIndex admissionCare algorithmHeart failureMortality outcomesDelays in antibiotic redosing: Association with inpatient mortality and risk factors for delay
Kemmler CB, Sangal RB, Rothenberg C, Li SX, Shofer FS, Abella BS, Venkatesh AK, Foster SD. Delays in antibiotic redosing: Association with inpatient mortality and risk factors for delay. The American Journal Of Emergency Medicine 2021, 46: 63-69. PMID: 33735698, DOI: 10.1016/j.ajem.2021.02.058.Peer-Reviewed Original ResearchConceptsSecond dose administrationEmergency departmentDose administrationRisk factorsEmergency Severity IndexHospital mortalityFirst doseSecond doseED boardingAntibiotic dosesEnd-stage renal diseaseExtremes of weightHigh acuity presentationsRetrospective cohort studyStage renal diseaseWorse clinical outcomesSerious bacterial infectionsOdds of delayEarly hospital courseSingle healthcare systemAntibiotic redosingDosing intervalHospital courseCohort studyInpatient mortalitySARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut
Mahajan S, Caraballo C, Li SX, Dong Y, Chen L, Huston SK, Srinivasan R, Redlich CA, Ko AI, Faust JS, Forman HP, Krumholz HM. SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut. The American Journal Of Medicine 2021, 134: 812-816.e2. PMID: 33617808, PMCID: PMC7895685, DOI: 10.1016/j.amjmed.2021.01.020.Peer-Reviewed Original ResearchConceptsInfection hospitalization rateInfection fatality rateHospitalization ratesFatality rateSeroprevalence estimatesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2 antibodiesConnecticut Hospital AssociationNon-Hispanic black peopleProportion of deathsCoronavirus disease 2019Total infected individualsTotal hospitalizationsAdverse outcomesNon-congregate settingsHigh burdenDisease 2019Prevalence studyMost subgroupsInfected individualsHospitalizationOlder peopleHospital AssociationConnecticut DepartmentDeathSuicide Deaths During the COVID-19 Stay-at-Home Advisory in Massachusetts, March to May 2020
Faust JS, Shah SB, Du C, Li SX, Lin Z, Krumholz HM. Suicide Deaths During the COVID-19 Stay-at-Home Advisory in Massachusetts, March to May 2020. JAMA Network Open 2021, 4: e2034273. PMID: 33475750, PMCID: PMC7821026, DOI: 10.1001/jamanetworkopen.2020.34273.Peer-Reviewed Original Research
2020
Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, Massey DS, Dugan A, Witters D, Marlar J, Li SX, Lin Z, Hodge D, Chattopadhyay M, Adams MD, Lee C, Rao LV, Stewart C, Kuppusamy K, Ko AI, Krumholz HM. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. The American Journal Of Medicine 2020, 134: 526-534.e11. PMID: 33130124, PMCID: PMC7598362, DOI: 10.1016/j.amjmed.2020.09.024.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific IgG antibodiesWeighted seroprevalenceIgG antibodiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2-specific antibodiesConnecticut residentsSelf-reported adherenceImmunoglobulin G antibodiesSARS-CoV-2Symptomatic illnessSerology testingSeroprevalence studyG antibodiesPrevalence studyGeneral populationPercentage of peopleSeroprevalenceLack antibodiesMajority of respondentsAntibodiesHispanic subpopulationsConvenience sampleHispanic populationCOVID-19Risk mitigation behaviorsTimely estimation of National Admission, readmission, and observation-stay rates in medicare patients with acute myocardial infarction, heart failure, or pneumonia using near real-time claims data
Li SX, Wang Y, Lama SD, Schwartz J, Herrin J, Mei H, Lin Z, Bernheim SM, Spivack S, Krumholz HM, Suter LG. Timely estimation of National Admission, readmission, and observation-stay rates in medicare patients with acute myocardial infarction, heart failure, or pneumonia using near real-time claims data. BMC Health Services Research 2020, 20: 733. PMID: 32778098, PMCID: PMC7416804, DOI: 10.1186/s12913-020-05611-w.Peer-Reviewed Original ResearchSurgeons: Buyer beware—does “universal” risk prediction model apply to patients universally?
Mori M, Shahian DM, Huang C, Li SX, Normand ST, Geirsson A, Krumholz HM. Surgeons: Buyer beware—does “universal” risk prediction model apply to patients universally? Journal Of Thoracic And Cardiovascular Surgery 2020, 160: 176-179.e2. PMID: 32241616, DOI: 10.1016/j.jtcvs.2019.11.144.Peer-Reviewed Original Research